文献速递糖尿病

美曲普汀治疗1型糖尿病患者的疗效与安全性:一项先导研究

Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study.
PubMed 文献 · Diabetes Care · 2017-02-21

该先导研究纳入8例控制欠佳的1型糖尿病患者,先经4周基线期,随后接受美曲普汀皮下注射20周(女性0.08 mg/kg/天、男性0.04 mg/kg/天,每日两次),之后停药4周。结果显示美曲普汀未显著降低HbA1c,但显著降低体重和每日胰岛素剂量。结论认为美曲普汀安全,但可能不能有效改善1型糖尿病患者的血糖控制。

要点

  • 美曲普汀未显著降低1型糖尿病患者的HbA1c。
  • 美曲普汀使体重和每日胰岛素剂量显著降低。
  • 美曲普汀在这8例1型糖尿病患者中安全性良好。

核心结论

  • 美曲普汀在1型糖尿病患者中安全,但可能不能有效改善血糖控制,尽管可适度降低体重和每日胰岛素剂量。

研究设计与样本

  • 先导研究:8例1型糖尿病患者(5例女性、3例男性,平均年龄33岁,BMI 23.8 kg/m2)先经4周基线期,随后接受美曲普汀皮下注射20周(女性0.08 mg/kg/天、男性0.04 mg/kg/天,每日两次),之后停药4周。

主要发现

  • 与基线相比,美曲普汀治疗未显著降低HbA1c:第12周平均差值-0.19%(-2.0 mmol/mol),第20周平均差值-0.04%(-0.5 mmol/mol)。
  • 与基线相比,平均体重在第12周和第20周分别显著降低2.6 kg和4.7 kg(P = 0.003)。
  • 与基线相比,每日胰岛素剂量在第12周和第20周分别显著降低12.6%和15.0%(P = 0.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference -0.19% [-2.0 mmol/mol] and -0.04% [-0.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6% and 15.0% at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Vasandani C, Clark GO, Adams-Huet B, et al. Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study. Diabetes Care. 2017. PMID: 28223297. doi:10.2337/dc16-1553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。